The pharmacology of cefotaxime and the metabolite desacetyl cefotaxime was studied in 40 patients with various degrees of renal and hepatic failure who received 0.5 or 1 g of cefotaxime intravenously. Patients with severe renal impairment (creatinine clearance, 3 to 10 ml/min) had a cefotaxiime serum halflife of 2.6 h and desacetyl cefotaxrime serum half-life of 10.0 h. The equivalent figures were 1.0 and 1.5 h, respectively, in subjects with normal renal function. The presence of an acute coexisting illness together with severe renal impairment was associated with a further prolongation of the serum half-lives. Hepatic dysfunction was accompanied by a reduction in desacetyl metabolite formation. A reduction of cefotaxime dosing to 0.5 g twice a day would appear prudent when the creatinine clearance is 5 ml/min or less to avoid accumulation of the parent compound and the metabolite.
The novel cephalosporin cefotaxime combines a broad antibacterial spectrum with considerable antimicrobial potency (2, 10) . This compound, like cephalothin and cephacetrile, possesses an acetoxy group on the 3 position of the cephem nucleus and undergoes desacetylation in animals and humans (7) . Desacetyl cefotaxime has a good antibacterial spectrum and potency, being similar to cefamandole and cefuroxime (11) . As little is known of the pharmacology of both the parent drug and the metabolite, this study was designed to investigate both cefotaxime and desacetyl cefotaxime in patients with various degrees of renal failure and also in patients with hepatic necrosis. A dosing regime is proposed.
MATERIALS AND METHODS
Patients. A total of 40 patients (19 males; mean age, 51.4 years) were studied after informed consent had been obtained. Thirty-four of these were under investigation for acute or chronic renal failure, and six patients had acute hepatocellular damage related to self-administered drugs such as acetaminophen and carbon tetrachloride. Thirty-eight patients received 1 g and 2 patients received 0.5 g of cefotaxime diluted in sterile water intravenously over 3 to 5 min. Creatinine clearance studies were performed during and after each investigation. Routine screening tests performed before and after the investigation consisted of a full blood count, blood urea, electrolytes, and liver function tests. In addition, the extent of the hepatocellular damage in five patients was gauged by the peak alanine-amino transferase activity measured daily. These six patients were all studied in the early recovery phase of their disease.
Three of the 34 patients with renal dysfunction were studied while undergoing hemodialysis with an Ultraflow (Travenol Laboratories S.A., Castlebar, County Mayo, Ireland) 1-m2 coil and a blood flow of 140 to 250 ml/min. Five patients underwent peritoneal dialysis (1.5-liter exchanges every 40 min) while being studied.
Repeated intravenous doses of 0.5 or 1 g of cefotaxime at 12-or 24-h intervals over 3 days were given to eight patients with renal dysfunction.
The patients with renal dysfunction were classified into four groups on the basis of their creatinine clearance (Table 1) . The group of patients with severe renal failure was further subdivided according to the presence or absence of acute illnesses (these included coexistent heart failure, septicemia, and pulmonary edema).
Sampling. Blood 3.125 .ug/ml were prepared in pooled human serum (pH 7.4) and injected before the first samples and after every sixth sample. All samples were run in triplicate, and serum levels were calculated from peak height measurements.
The high-performance liquid chromatographic assay had previously been compared with a bioassay designed to measure cefotaxime by using Proteus morganii as an indicator organism (8) . The correlation coefficient between the two assays was calculated as r = 0.98. Deepfreezing for periods of up to 1 week had been shown not to alter assay results.
Hematology and biochemistry. The hematological and biochemical tests were performed by standard methods. In particular the creatinine concentrations in urine and serum were measured by the colorimetric method of Jaffe as described by Bosnes and Tausky (1).
Pharmacokinetic analysis. The data were analyzed by least squares regression line analysis. Pharmacokinetic parameters were calculated by using a two-compartment model (6) . Serum half-lives were calculated from analysis of the beta phase of elimination. The central volume of distribution (Vc) was calculated from the formula Vc = Do/A + B, where A and B are the theoretical concentrations obtained by extrapolating the a and ,B exponentials back to time zero, and Do is the dose given (3).
RESULTS
Renal dysfunction. The results of cefotaxime and desacetyl cefotaxime elimination studies in patients with various degrees of renal failure are shown in Table 1 . For technical reasons (interfering peaks on high-performance liquid chromatography) it was not always possible to assay the desacetyl metabolite. The serum half-lives of cefotaxime in all patients in the study are shown in Fig. 1 . The serum half-life of cefotaxime barely doubled when the creatinine clearance fell from nornal to between 10 to 30 ml/min (Table 1) . Patients with a severe impairment of renal function (creatinine clearance, 3 to 10 ml/min) had a mean cefotaxime serum half-life of 2.6 h. Patients with severe coexisting disease in addition to severe renal failure had varied but generally more prolonged serum halflives. The elimination of desacetyl cefotaxime was more markedly reduced in patients with renal failure (Fig. 2) . When the elimination constant was plotted against creatinine clearance the relationship approximated towards linearity (for cefotaxime, r = 0.84, n = 32; for desacetyl cefotaxime, r = 0.88, n = 13). The mean amount of cefotaxime appearing in the urine in five subjects with normal renal function after intravenous administration of 1 g was 680 mg, whereas the mean amount in five subjects with creatinine clearances of less than 5 ml/min was 147 mg. Calculated volumes of distribution of cefotaxime in these two groups were 0.22 and 0.15 liter/kg, respectively, a slight reduction in the patients with reduced renal function.
Only miniimal amounts of cefotaxime appeared in the peritoneal dialysate of five patients. The mean serum cefotaxime half-life during dialysis (2.9 h ± 1.08 [standard deviation]) did not differ significantly from that found in this same group when they were not on dialysis (4.4 h ± 4.1 [standard deviation]). In contrast, hemodialysis caused a mean reduction in cefotaxime serum half-life of 44% as compared with the drug half-life in the same patients when they were not on hemodialysis.
Eight patients were studied after repeated doses ( Table 2 ). The case of a male 42-year-old patient who was given 1 g twice daily is illustrated in Fig. 3 . Slight cefotaxime accumulation occurred in patients given 1 g twice daily, but only to a minimal degree in those given 0.5 g twice daily. Accumulation of the desacetyl metabolite occurred in all patients with severe renal failure whatever the dosing regime. It was of a minor degree (48%) in patients given 0.5 g twice daily. There was no evidence that this was accompanied by any toxic effects. Hepatic dysfunction. Data on six patients with hepatic damage are summarized in Table  3 . The amount of desacetyl cefotaximne formed (as measured by peak levels) was reduced with increasing liver damage when assessed by serum aspartate transaiinase. There was also an increase in cefotaxime half-life with a reduction in renal function (assessed by creatinine clearance).
This increase was ielated to the extent of renal function rather than reduced metabolic capacity. Two-hour levels were remarkably high in two patients, but there was no obvious reason for this.
Toxicity. There was no evidence of drug-associated deterioration in renal function, hepatic damage, or hematological disturbance, and no phlebitis was noted. Nausea occurred in one patient given the drug more rapidly than usual (over 2 min instead of the standard 5 min). DISCUSSION Cefotaxime clearance from serum was reduced in patients with renal failure, but not to the same extent as that occurring with antimicrobial agents that are eliminated solely by the kidneys (9) . This difference is presumably related to metabolism of cefotaxime to the desacetyl compound. Cefotaxime clearance was markedly depressed only when renal function fell below a creatinine clearance of 10 ml/min, and drug elimination was unpredictable when the patient also suffered from concurrent severe illness (in one case the half-life was as long as 11.5 h). Others have reported that severe illness alters drug disposition (5) and can greatly reduce overall elimination (4) .
Desacetyl cefotaxime would appear to be eliminated almost solely by the kidneys, as the serum half-life was increased to a greater extent in patients with concurrent renal failure. As indicated by multiple dose studies, accumulation occurred to a greater degree with desacetyl cefotaxime than with the parent compound in patients with severe renal failure. Interestingly, concurrent hepatic damage depressed desacetyl cefotaxime formation, but did not affect overall cefotaxime elimination.
In arriving at any conclusions relating to a dosing schedule of an antibiotic the antibacterial activity has to be considered. It is not possible to give a definite dosing schedule but, as many common pathogens are extremely susceptible to cefotaxime (2, 10) , and as dosing every 8 to 12 h with 1 g appears to be adequate in clinical trials (7) , this would appear to be a reasonable starting point to consider for a dosing schedule for a patient with renal failure. As cefotaxime is eliminated by extrarenal mechanisms (i.e., is metabolized), accumulation hardly occurs with 1-g dosing even when the creatinine clearance falls to 10 ml/min. Below this level of renal function cefotax2ime accumulation was only minor. Desacetyl cefotaxime accumulation in patients with severe renal failure after multiple dosing was somewhat more marked, but not excessive (it did not exceed 65 ,ug/ml even in patients given 1 g twice daily), and was not accompanied by any toxic effects.
When renal function is severely reduced (i.e., a creatinine clearance of 5 ml/min), the halflives of cefotaxime and its metabolite are extremely variable, and it would appear prudent to reduce dosing to 0.5 g twice daily. Peritoneal dialysis and hepatic necrosis do not materially affect cefotaxime elimination; hence, dosing schedules need not be altered in these conditions. Hemodialysis may require some increase in dose. In all other conditions 1 g of cefotaxime twice daily would appear to be an adequate and safe dosing schedule. Further alterations could be made, for patients without severe renal failure, if indicated by the severity of the infection.
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